Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CBIO Crescent Biopharma Inc.
- Stocks
- Healthcare
- NASDAQ: CBIO
Price (delayed)
$15.89
Market cap
$10.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$46
Enterprise value
$4.64M
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is
Highlights
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
The company's EPS rose by 22% QoQ and by 21% YoY
CBIO's quick ratio has shrunk by 64% YoY but it is up by 16% QoQ
Crescent Biopharma's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of CBIO
Market
Valuations
Earnings
Shares outstanding
645,321
Market cap
$10.25M
Enterprise value
$4.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.32M
Net income
-$29.49M
EBIT
-$29.49M
EBITDA
-$29.23M
Free cash flow
-$25.67M
Per share
Balance sheet
Liquidity
EPS
-$46
EPS diluted
-$46
Free cash flow per share
-$39.78
Book value per share
$5.23
Revenue per share
$0
TBVPS
$9.29
Total assets
$5.99M
Total liabilities
$2.62M
Debt
$0
Equity
$3.38M
Working capital
$3.38M
Debt to equity
0
Current ratio
2.29
Quick ratio
2.15
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-206.2%
Return on equity
-293.9%
Return on invested capital
N/A
Return on capital employed
-873.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CBIO stock price
How has the Crescent Biopharma stock price performed over time
Intraday
2.22%
1 week
-5.98%
1 month
-23.97%
1 year
-41.82%
YTD
-36.18%
QTD
-1.55%
Financial performance
How have Crescent Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.32M
Net income
-$29.49M
Gross margin
N/A
Net margin
N/A
Crescent Biopharma's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
Crescent Biopharma's operating income has increased by 22% from the previous quarter and by 21% YoY
Crescent Biopharma's net income has increased by 22% QoQ and by 21% YoY
Price vs fundamentals
How does CBIO's price correlate with its fundamentals
Growth
What is Crescent Biopharma's growth rate over time
Valuation
What is Crescent Biopharma stock price valuation
P/E
N/A
P/B
3.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 22% QoQ and by 21% YoY
Crescent Biopharma's equity has plunged by 88% YoY and by 36% from the previous quarter
CBIO's price to book (P/B) is 52% higher than its 5-year quarterly average of 2.0 and 38% higher than its last 4 quarters average of 2.2
Crescent Biopharma's revenue has plunged by 100% YoY
Efficiency
How efficient is Crescent Biopharma business performance
Crescent Biopharma's return on assets has shrunk by 169% YoY and by 16% QoQ
The ROE has contracted by 27% from the previous quarter
Dividends
What is CBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CBIO.
Financial health
How did Crescent Biopharma financials performed over time
The total assets is 129% more than the total liabilities
The total assets has plunged by 82% YoY and by 46% from the previous quarter
Crescent Biopharma's current ratio has shrunk by 64% YoY but it has increased by 19% QoQ
The debt is 100% smaller than the equity
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
CBIO's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.